Literature DB >> 16759858

The interaction between tylophorine B and TMV RNA.

Zhen Xi1, Ruoyu Zhang, Zhihong Yu, Di Ouyang.   

Abstract

Tylophorine B exhibits 60% inhibition against tobacco mosaic virus (TMV) at a concentration of 1.0 x 10(-6) g/ml. In our study, high affinity for TMV RNA and assembly origin of TMV RNA (oriRNA) was revealed, accompanied by the conformational change of RNA. Considering that TMV assembly begins with the specific recognition by the coat protein aggregate of oriRNA, and that tylophorine B has favorable interaction with oriRNA, we speculate that tylophorine B likely exerts its virus inhibition by binding to oriRNA and interfering with virus assembly initiation. This work may shed light on the possible molecular inhibition mechanism against TMV by tylophorine B, and provide clues in rational design of sequence-specific RNA binding antivirus drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759858     DOI: 10.1016/j.bmcl.2006.05.059

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Total synthesis of (S)-(+)-tylophorine via enantioselective intramolecular alkene carboamination.

Authors:  Wei Zeng; Sherry R Chemler
Journal:  J Org Chem       Date:  2008-06-28       Impact factor: 4.354

2.  Antitumor agents 288: design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents.

Authors:  Xiaoming Yang; Qian Shi; Shuenn-Chen Yang; Chi-Yuan Chen; Sung-Liang Yu; Kenneth F Bastow; Susan L Morris-Natschke; Pei-Chi Wu; Chin-Yu Lai; Tian-Shung Wu; Shiow-Lin Pan; Che-Ming Teng; Jau-Chen Lin; Pan-Chyr Yang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

3.  Total syntheses of arylindolizidine alkaloids (+)-ipalbidine and (+)-antofine.

Authors:  Micah J Niphakis; Gunda I Georg
Journal:  J Org Chem       Date:  2010-09-03       Impact factor: 4.354

4.  Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy.

Authors:  Sherry R Chemler
Journal:  Curr Bioact Compd       Date:  2009-03-01

5.  Total synthesis of phenanthroindolizidine alkaloids (+/-)-antofine, (+/-)-deoxypergularinine, and their dehydro congeners and evaluation of their cytotoxic activity.

Authors:  Chung-Ren Su; Amooru G Damu; Po-Cheng Chiang; Kenneth F Bastow; Susan L Morris-Natschke; Kuo-Hsiung Lee; Tian-Shung Wu
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

6.  Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of glycoconjugates of phenanthroindolizidines alkaloids.

Authors:  Meng Wu; Guifang Han; Chuisong Meng; Ziwen Wang; Yuxiu Liu; Qingmin Wang
Journal:  Mol Divers       Date:  2013-10-17       Impact factor: 2.943

7.  New Strategies and Methods to Study Interactions between Tobacco Mosaic Virus Coat Protein and Its Inhibitors.

Authors:  Xiangyang Li; Zhuo Chen; Linhong Jin; Deyu Hu; Song Yang
Journal:  Int J Mol Sci       Date:  2016-02-26       Impact factor: 5.923

Review 8.  In vitro thermotherapy-based methods for plant virus eradication.

Authors:  Min-Rui Wang; Zhen-Hua Cui; Jing-Wei Li; Xin-Yi Hao; Lei Zhao; Qiao-Chun Wang
Journal:  Plant Methods       Date:  2018-10-06       Impact factor: 4.993

Review 9.  Possible pharmaceutical applications can be developed from naturally occurring phenanthroindolizidine and phenanthroquinolizidine alkaloids.

Authors:  Xian-Hui Jia; Huan-Xin Zhao; Cheng-Lin Du; Wen-Zhao Tang; Xiao-Jing Wang
Journal:  Phytochem Rev       Date:  2020-09-25       Impact factor: 7.741

10.  Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis.

Authors:  Sarita Saraswati; Pawan K Kanaujia; Shakti Kumar; Ranjeet Kumar; Abdulqader A Alhaider
Journal:  Mol Cancer       Date:  2013-07-29       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.